Prostate cancer drug gets thumbs up

New drug trial results offer hope to men with advanced prostate cancer and will change the way the disease is treated, says the Urological Society of Australia and New Zealand (USANZ).

Two significant studies have found that earlier use of the drug abiraterone, which is a steroidal CYP17A1 inhibitor, increases life expectancy.

Currently men with advanced prostate cancer are treated with androgen deprivation therapy (ADT).